Genmab — August 2020

[Helge_LarsenPI-redaktør]

Med hensyn til Q&A får jeg snart en dato fra Genmab.

[E_L]

Amivantamab (JNJ-61186372), An Fc Enhanced EGFR/cMet Bispecific Antibody Induces Receptor Downmodulation And Anti-tumor Activity By Monocyte/Macrophage Trogocytosis https://mct.aacrjournals.org/content/early/2020/08/01/1535-7163.MCT-20-0071?sf126366784=1

[bibob]

God morgen. :-). Så er der bestilt mundbind. Håber ikke jeg får brug for dem. ;-).

[Helge_LarsenPI-redaktør]

God morgen.

[Helge_LarsenPI-redaktør]

Q&A med Jan bliver d. 26/8 kl 16,30-17,15.

[Solsen]

Super Helge

[E_L]

https://seekingalpha.com/article/4367315-halozyme-therapeutics-halo-ceo-helen-torley-on-q2-2020-results-earnings-call-transcript?part=single Halozyme Therapeutics' (HALO) CEO Helen Torley on Q2 2020 Results - Earnings Call Transcript

[Hamming]

Der er Second Quarter 2020 update fra Biontech i dag. Måske noget gen relateret?

[Hamming]

https://investors.biontech.de/events/event-details/second-quarter-2020-update

[Mcjean]

Have you seen the result from AL Amyloidosis 14 june?

[Mcjean]

mentioned in the Halozyme transcript?

[Mcjean]

Pretty impressive!

[E_L]

yes, we had the EHA abstract here, and i think Genmab had a press release on it end may or early june, you should be able to find it via the search here

[E_L]

only waiting for JNJ to file it now

[E_L]

2 articles on Trogocytosis , as per the Amivantamab link yesterday https://www.pnas.org/content/116/36/17608 https://www.nature.com/articles/ni0903-815

[Solsen]

As I understod did they the right thing when they tested Amivantamab preclinical as immune cells where added - then the dose effect became clear. The article just emphazise the importance doing that when preclinical work are done ?

[E_L]

i think it is a bit more then that , "Collectively, these findings demonstrate that amivantamab Fc-interaction with macrophages and
monocytes induces trogocytosis which is a dominant mechanism underlying the anti-tumor

efficacy of amivantamab."

[E_L]

"Previously, trogocytosis was described as a mechanism of resistance for antibodies such as

However, in this study, we demonstrated a novel role for

trogocytosis (ADCT) as a crucial inducer of Fc-dependent receptor downmodulation and antitumor
effects.

[E_L]

In addition to targeting a
conserved region of an oncogenic receptor, which broadens the targeted population, the
selectivity of bispecific antibodies like amivantamab, could offer a reduced potential for toxicity,
making combination therapy with additional agents better tolerated.

[E_L]

Our findings demonstrate
that the Fc-dependent activity of amivantamab is driven by macrophage- and monocyte-mediated
trogocytosis, a dominant mechanism of antibody-directed receptor downregulation and tumor
cell killing. These findings highlight the potential of trogocytosis as therapeutic modality but also
provide insights to guide patient selection and combination strategies for amivantamab."